Aerie Pharma Prices IPO Of 6.72 Mln Shares At $10 Per Share

(RTTNews) - Aerie Pharmaceuticals, Inc., Friday priced its initial public offering of 6.72 million common shares at $10 per share, before underwriting discounts. The shares are scheduled to begin trading on October 25, under the ticker 'AERI' on the Nasdaq.

Further, the underwriters have been granted a 30-day option to purchase up to an additional 1,008,000 common shares, at the same price to cover over-allotments, if any. The offering is expected to close on October 30.

RBC Capital Markets and Stifel are serving as joint book-running managers for the offering. Canaccord Genuity Inc. and Needham & Company are serving as co-managers.

Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.